deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03228186

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Sponsor: University of Michigan Rogel Cancer Center

Conditions Non-small Cell Lung Cancer
Interventions Docetaxel Pevonedistat
Updated 15 times since 2017 Last updated: Oct 5, 2023 Started: Mar 5, 2018 Primary completion: Nov 4, 2021 Completion: Nov 4, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Pharmaceutical company discontinued the study drug.

Other terminated trials from University of Michigan Rogel Cancer Center

See all terminations from University of Michigan Rogel Cancer Center

Other Non-small Cell Lung Cancer trials with similar outcome

Browse all Non-small Cell Lung Cancer trials

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently terminated or withdrawn. University of Michigan Rogel Cancer Center leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Nov 2019 · 9 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Nov 2023 · 21 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Feb 2022 — Nov 2023 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Jan 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  2. Jul 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  3. May 2020 — Jul 2020 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  4. Dec 2019 — May 2020 [monthly]

    Recruiting PHASE2

  5. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  7. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Aug 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Michigan Rogel Cancer Center
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations